Skip to main content

Table 5 Immune checkpoint inhibitors, Treatment response in NSCLC

From: The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study

 TotalATBno ATBp value TotalATBno ATBp value
CR0000.006OR29 (24%)8 (16%)21 (30%)0.085
PR29 (24%)8 (16%)21 (30%) nOR92 (76%)42 (84%)50 (70%) 
SD51 (42%)17 (34%)34 (48%) DC80 (66%)25 (50%)55 (78%)0.002
PD41 (34%)25 (50%)16 (22%) nDC41 (34%)25 (50%)16 (22%) 
Total1215071 Total1215071 
  1. Non-evaluated, N = 10
  2. ATB Antibiotics